Arcadia Biosciences Inc
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief,… Read more
Arcadia Biosciences Inc (RKDA) - Net Assets
Latest net assets as of September 2025: $5.44 Million USD
Based on the latest financial reports, Arcadia Biosciences Inc (RKDA) has net assets worth $5.44 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.58 Million) and total liabilities ($3.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.44 Million |
| % of Total Assets | 63.41% |
| Annual Growth Rate | N/A |
| 5-Year Change | -78.2% |
| 10-Year Change | -84.53% |
| Growth Volatility | 91.3 |
Arcadia Biosciences Inc - Net Assets Trend (2012–2024)
This chart illustrates how Arcadia Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Arcadia Biosciences Inc (2012–2024)
The table below shows the annual net assets of Arcadia Biosciences Inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $6.22 Million | -51.01% |
| 2023-12-31 | $12.70 Million | -39.22% |
| 2022-12-31 | $20.90 Million | -33.00% |
| 2021-12-31 | $31.20 Million | +9.26% |
| 2020-12-31 | $28.55 Million | +242.93% |
| 2019-12-31 | $8.33 Million | -35.03% |
| 2018-12-31 | $12.81 Million | +60.05% |
| 2017-12-31 | $8.01 Million | -63.93% |
| 2016-12-31 | $22.20 Million | -44.82% |
| 2015-12-31 | $40.23 Million | +2233.95% |
| 2014-12-31 | $-1.89 Million | +89.10% |
| 2013-12-31 | $-17.30 Million | -204.31% |
| 2012-12-31 | $-5.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arcadia Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19644200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $65.00K | 1.04% |
| Other Components | $285.04 Million | 4580.36% |
| Total Equity | $6.22 Million | 100.00% |
Arcadia Biosciences Inc Competitors by Market Cap
The table below lists competitors of Arcadia Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ARHT Media Inc
OTCQB:ARHTF
|
$2.35 Million |
|
HIKARI TSUSHIN
MU:HIK
|
$2.35 Million |
|
Wästbygg Gruppen AB (publ)
ST:WBGR-B
|
$2.35 Million |
|
Duta Anggada Realty Tbk
JK:DART
|
$2.35 Million |
|
AKS Corporation Public Company Limited
BK:AKS
|
$2.35 Million |
|
XP Chemistries AB
ST:XPC
|
$2.35 Million |
|
Nl Development Public Company Limited
BK:NL
|
$2.35 Million |
|
NEVADA SUNRISE METALS
F:K4L
|
$2.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arcadia Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,841,000 to 6,223,000, a change of -6,618,000 (-51.5%).
- Net loss of 7,038,000 reduced equity.
- Other comprehensive income decreased equity by 101,000.
- Other factors increased equity by 521,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.04 Million | -113.1% |
| Other Comprehensive Income | $-101.00K | -1.62% |
| Other Changes | $521.00K | +8.37% |
| Total Change | $- | -51.54% |
Book Value vs Market Value Analysis
This analysis compares Arcadia Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.38x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-138.97 | $1.72 | x |
| 2013-12-31 | $-422.91 | $1.72 | x |
| 2014-12-31 | $-46.09 | $1.72 | x |
| 2015-12-31 | $1126.81 | $1.72 | x |
| 2016-12-31 | $400.27 | $1.72 | x |
| 2017-12-31 | $148.54 | $1.72 | x |
| 2018-12-31 | $136.10 | $1.72 | x |
| 2019-12-31 | $48.44 | $1.72 | x |
| 2020-12-31 | $111.36 | $1.72 | x |
| 2021-12-31 | $58.44 | $1.72 | x |
| 2022-12-31 | $35.09 | $1.72 | x |
| 2023-12-31 | $10.38 | $1.72 | x |
| 2024-12-31 | $4.56 | $1.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arcadia Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -113.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -139.50%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 2.17x
- Recent ROE (-113.10%) is below the historical average (-89.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -176.46% | 0.52x | 0.00x | $-11.80 Million |
| 2013 | 0.00% | -203.69% | 0.68x | 0.00x | $-11.47 Million |
| 2014 | 0.00% | -262.66% | 0.28x | 0.00x | $-18.15 Million |
| 2015 | -44.64% | -331.66% | 0.07x | 1.85x | $-21.98 Million |
| 2016 | -88.40% | -615.56% | 0.06x | 2.55x | $-21.84 Million |
| 2017 | -196.17% | -390.14% | 0.24x | 2.07x | $-16.51 Million |
| 2018 | -105.19% | -920.77% | 0.06x | 1.87x | $-14.76 Million |
| 2019 | -373.85% | -2464.07% | 0.04x | 4.23x | $-29.58 Million |
| 2020 | -16.79% | -57.94% | 0.17x | 1.71x | $-7.43 Million |
| 2021 | -47.15% | -216.22% | 0.15x | 1.41x | $-17.77 Million |
| 2022 | -73.10% | -207.28% | 0.26x | 1.38x | $-17.48 Million |
| 2023 | -108.88% | -313.90% | 0.23x | 1.53x | $-15.27 Million |
| 2024 | -113.10% | -139.50% | 0.37x | 2.17x | $-7.66 Million |
Industry Comparison
This section compares Arcadia Biosciences Inc's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $5,681,533,529
- Average return on equity (ROE) among peers: 0.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arcadia Biosciences Inc (RKDA) | $5.44 Million | 0.00% | 0.58x | $2.35 Million |
| Above Food Ingredients Inc. Common Stock (ABVE) | $30.90K | -3.31% | 7.66x | $18.76 Million |
| The a2 Milk Company Limited (ACOPF) | $7.27 Million | -30.19% | 0.14x | $3.91 Billion |
| Ayujoy Herbals Ltd (AJOY) | $22.20 Million | 29.29% | 0.00x | $95.71 |
| Alfa S.A.B. de C.V (ALFFF) | $53.35 Billion | 7.36% | 3.80x | $2.16 Billion |
| Amincor Inc (AMNCB) | $34.44 Million | -63.76% | 0.81x | $2.24K |
| Armanino Foods New (AMNF) | $21.40 Million | 30.30% | 0.33x | $72.33K |
| Amira Nature Foods Ltd (ANFIF) | $303.22 Million | 8.27% | 0.89x | $128.79 |
| AAK AB (publ.) (ARHUF) | $2.44 Billion | 12.85% | 2.63x | $5.07 Billion |
| Artisan Consumer Goods Inc (ARRT) | $-326.75K | 0.00% | 0.00x | $279.39K |
| ARYZTA AG (ARZTF) | $632.10 Million | 9.58% | 2.04x | $53.13 Million |